Our platform transiently and non-invasively disrupts the blood-brain barrier, allowing targeted delivery of CNS molecules previously unable to reach the brain
Our platform transiently and non-invasively disrupts the blood-brain barrier, allowing targeted delivery of CNS molecules previously unable to reach the brain. We collaborate with pharmaceutical and biotech partners to rescue assets sidelined by BBB constraints.
Our platform transiently and non-invasively disrupts the blood-brain barrier, allowing targeted delivery of CNS molecules previously unable to reach the brain
Our platform transiently and non-invasively disrupts the blood-brain barrier, allowing targeted delivery of CNS molecules previously unable to reach the brain. We collaborate with pharmaceutical and biotech partners to rescue assets sidelined by BBB constraints.